Q32 Bio, a clinical-stage biotechnology company focused on developing biological therapeutics for autoimmune and inflammatory diseases, is led by Jodie Morrison. Serving as the Chief Executive Officer and a member of the Board of Directors, she brings extensive executive leadership experience spanning private start-ups and public biotechnology corporations. Her professional background includes guiding multiple biopharmaceutical firms through critical clinical developments, public market offerings, and strategic corporate acquisitions prior to taking the helm at Q32 Bio.